Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:48:12.866Z.
Consensus retrieved: 2026-10-06T16:22:51.817Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:48:12.866Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69957a8c264286ff6eaa706b48c8270e863bf40c8b9bfd4321b5f2d082882a11
Forward PE Ratio (N/A) = Dated Quote Price ($4.75) / Consensus Forward EPS ($-2.48)
FORWARD PE RATIO
N/A
Sionna Therapeutics, Inc.
Market Cap
$214.46M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Sionna Therapeutics, Inc. (SION) | $214.46M | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 18.65 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | N/A |
| Compugen Ltd. (CGEN)vs › | $209.91M | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A |
| Profound Medical Corp. (PROF)vs › | $220.93M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $4.75, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.48 | $-2.68 – $-2.22 | 8 | n/m |
| 2027-12-31 | $-2.29 | $-3.33 – $-1.64 | 8 | n/m |
| 2028-12-31 | $-2.60 | $-3.86 – $-1.45 | 8 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
